n funding...2019/01/05 · awarded. seed financing round completed. • 2015: series a financing...
TRANSCRIPT
1F R E E M I N D 1 4 t h N D F S
N E X T G E N E R AT I O N D I S E A S E T E S T I N G
OUR NON-DILUTIVE FUNDING JOURNEY
January 9th 2019
2F R E E M I N D 1 4 t h N D F S
WHO ARE WE?
3F R E E M I N D 1 4 t h N D F S
• 2012: 1st SBIR Phase 1 NIH Grant Awarded
• 2013: Company Founded. Key IP
Generated. Joined UC Berkeley QB3 and
StartX Incubators.
• 2014: NIH and NSF Phase 1 Grants
Awarded. Seed Financing Round
Completed.
• 2015: Series A Financing Round Completed
• 2016: NIH Phase 2 Grants Awarded
• 2017: First Patents Granted. Pilot Clinical
Trials Completed
• 2018: BARDA Contract Awarded
COMPANY ORIGIN
4F R E E M I N D 1 4 t h N D F S
“Our mission is to break down barriers in access to healthcare. We
empower patients to manage their health at their convenience
without excessive costs.”
DIASSESS MISSION
5F R E E M I N D 1 4 t h N D F S
PARADIGM SHIFTS IN MOLECULAR DIAGNOSTICS
CENTRALIZED LAB TESTING
Throughput
Per
Test
Co
st R
ed
uct
ion
Manual Testing
Automated Testing
Inspired by ”The Innovator ’s Prescription”
6F R E E M I N D 1 4 t h N D F S
PARADIGM SHIFTS IN MOLECULAR DIAGNOSTICS
POINT-OF-CARE / NEAR PATIENT TESTING
Ease of Use
Test
Sp
eed
CLIA-moderate
CLIA-waived
7F R E E M I N D 1 4 t h N D F S
AT-HOME / ON-MAN TESTING
Accessibility to health information
Per
Test
Co
st R
ed
uct
ion
PARADIGM SHIFTS IN MOLECULAR DIAGNOSTICS
DIASSESS
8F R E E M I N D 1 4 t h N D F S
Sample
Preparation Tube
Mobile App To
Enable PrescriptionDigital
Readout
DNA Test
Cartridge
Battery
Powered
Nasal Swab
AT-HOME TESTING AND TREATMENT
9F R E E M I N D 1 4 t h N D F S
PRESCRIPTION
OUT
TEST
RESULTS IN
DIRECT
DIGITAL
PRESCRIPTION
Send Prescription to Pharmacy
Connect to Telemedicine
10F R E E M I N D 1 4 t h N D F S
Prevalence
Monitoring
Network Effects
Supply Chain
Inform Consumer
Vaccines & Pharma
REAL-TIME DATA
Influenza 12/01/18 - 12/31/18
5
2 5
6
8
2
1`
1
1
2
11F R E E M I N D 1 4 t h N D F S
Slide from BARDA Industry Day 2018
AT-HOME INFLUENZA TESTING
12F R E E M I N D 1 4 t h N D F S
ONLY 45% of population is vaccinated every year!CDC. MMWR 62 2013
31.4MMOUTPATIENT VISITSMolinari NA, et al. Vaccine
25 (2007)
200,000HOSPITALIZATIONSZhou H et al. CID (2012)
BETWEEN
3,000 &
80,000 DEATHS*33,783 car deaths per year
for comparison
CDC. MMWR 59 2010
$10.4BNIN DIRECT
CLINICAL COSTSMolinari NA, et al. Vaccien
25 (2007)
17MMWORK DAYS MISSED
PER YEARMolinari NA, et al. Vaccine
25 (2007)
11 HOURSOF MISSED WORK
FOR SICK CHILD
CAREOrtega-Sanchex IR, et al.
Vaccine 30 (2012)
73 HOURSOF MISSED WORK
FOR CHILD
HOSPITALIZATIONOrtega-Sanchex IR, et al.
Vaccine 30 (2012)
$16.3BNIN LOST
EARNINGS
ANNUALLYMolinari NA, et al. Vaccine
25 (2007)
IMPACT OF FLU ON OUR ECONOMY EVERY YEAR
13F R E E M I N D 1 4 t h N D F S
O U TCO M E S E X P E R I E N C E
More Frequent Severe IllnessVisit Doctor Too Late
Unnecessary Sick Days Missed Work and Lost Wages
Wasted TimeWaiting Hours or Days for Doctor Visit
Cost Barrier to Entry$50 or More per Visit
POOR TREATMENT OPTIONS AND POOR OUTCOMES
14F R E E M I N D 1 4 t h N D F S
Schedule
Appointment
Visit Urgent
Care/ER RxRapid Test
Home
Test
Visit
Doctor RxRapid Test
Rx
HAVING FLU SHOULDN'T BE COSTLY & TIME CONSUMING
8 + H O U R S
$ 5 0 +
1 + H O U R
$ 1 1 0 +
3 0 M I N
$ 5 0
O U R
S O LU T I O N
15F R E E M I N D 1 4 t h N D F S
OUR NON-DILUTIVE FUNDING
JOURNEY
16F R E E M I N D 1 4 t h N D F S
NON-DILUTIVE FUNDING
$26M IN GRANTS /CONTRACTS
0
4
8
12
16
20
24
28
2013 2014 2015 2016 2017 2018 2019*No
n-D
ilutive
Fu
nd
ing
Rece
ived
(in
mill
ions)
Year
NIH NSF BARDA
* Anticipated
Seed funding
5 employees
TRL 2
Series A funding
10 employees
TRL 4
TRL 5
20 employees
TRL 6
40 employees
17F R E E M I N D 1 4 t h N D F S
GRANTS VS. CONTRACTS
SBIR / STTR GRANTS CONTRACTS
Purpose To advance public purpose To directly benefit the
government in performing
public duties
Scope of Work Defined by PI Defined by agency
Budgets and Cashflow Flexible funding instrument
“Drawdown accounts”
Binding goods / services
acquisition agreement
“Invoice payments”
18F R E E M I N D 1 4 t h N D F S
• Feb 2016 : BARDA Techwatch requested
• March 2016 : BARDA Techwatch
• January 2017: Whitepaper submitted
• May 22nd 2017 : Invitation to submit full proposal
• June 1st 2017 : FreeMind engagement started
• June 21st 2017 : Full Proposal submitted
• Nov 2017 : Proposal updates submitted
• Dec 2017 : Contract negotiations started
• April 2018 : BARDA site visit
• July 2018 : Final contract executed
BARDA CONTRACT TIMELINE
19F R E E M I N D 1 4 t h N D F S
• Persistence
• Listen to feedback
• Know the agency
• Identify partners
• Clear “Go-to-market” strategy
• Budget adequately
• Identify resource needs as an organization to execute
LESSONS LEARNED
20F R E E M I N D 1 4 t h N D F S
• Cost sharing
• Scope of negotiations post technical review
• Support provided by BARDA (staff and SMEs)
• Expanded in-house operational needs
- Program Management
- Data Management
- Invoicing
• Need for working capital
LESSONS LEARNED (BARDA CONTRACT)
21F R E E M I N D 1 4 t h N D F S